I promise” The video has been viewed by more than 60 million people And they aren't so sure Meagan is really “fine” Meagan ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

En Carta Diagnostics receives FDA Breakthrough Device Designation for EC Pocket Lyme test Breakthrough device status for rapid, Point-of-Need molecular diagnostic platform will fill critical gap in ...

Litifilimab is a humanized IgG1 monoclonal antibody targeting the BDCA2 receptor to reduce proinflammatory mediators in cutaneous lupus erythematosus.

Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage ...

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease ...

The pharma will vie for amlitelimab’s approval, despite the COAST 2 trial missing a co-primary endpoint.

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

From salon chair to doctor’s clinic, experts ‘nail down’ unhealthy fads after a surge in nail-related contact dermatitis ...

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Fremanezumab yields a greater reduction in the number of migraine days and headache days than placebo among children and ...